| Literature DB >> 24982884 |
Magdalena Zasada1, Przemko Kwinta1, Wojciech Durlak2, Mirosław Bik-Multanowski2, Anna Madetko-Talowska2, Jacek Józef Pietrzyk1.
Abstract
To expand the knowledge about the consecutive expression of genes involved in the immune system development in preterm neonates and to verify if the environment changes the gene expression after birth we conducted a prospective study that included three cohorts: (A) extremely (gestational age (GA): 23-26 weeks; n = 41), (B) very (GA: 27-29 weeks; n = 39), and (C) moderately preterm infants (GA: 30-32 weeks; n = 33). Blood samples were drawn from the study participants on the 5th and 28th day of life (DOL). The mRNA samples were evaluated for gene expression with the use of GeneChip Human Gene 1.0ST microarrays. Differential expression analysis revealed small subsets of genes that presented positive or negative monotone trends in both the 5th (138 genes) and 28th DOL (308 genes) in the three subgroups of patients. Based on pathway enrichment analysis, we found that most of the pathways that revealed a positive monotone trend were involved in host immunity. The most significantly GA dependent pathways were T-cell receptor signaling pathway and intestinal immune network for IgA production. Overall 4431 genes were differentially expressed between the 5th and 28th DOL. Despite differences in gestational age, patients with the same postconceptional age have a very similar expression of genes.Entities:
Mesh:
Year: 2014 PMID: 24982884 PMCID: PMC4058491 DOI: 10.1155/2014/498318
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Comparison of selected demographic data in the studied cohorts.
| Extremely preterm (23–26 weeks) ( | Very preterm (27–29 weeks) ( | Moderately preterm (30–32 weeks) ( |
| |
|---|---|---|---|---|
| Birth weight, g ( | 727 ± 124 | 1149 ± 207 | 1245 ± 211 | <0.001a |
| Gestational age (weeks) ( | 25.0 ± 1.1 | 28.2 ± 0.8 | 30.7 ± 0.8 | <0.001a |
| Male gender | 24 (58%) | 20 (51%) | 17 (52%) | 0.76b |
| Vaginal delivery/Cesarean section | 20/21 | 15/24 | 8/25 | 0.01b |
| Multiple pregnancy | 4 (10%) | 8 (20%) | 6 (18%) | 0.56b |
| Small-for-gestational-age infant | 4 (10%) | 1 (2%) | 5 (15%) | 0.1b |
| Maternal hypertension | 8 (19%) | 7 (18%) | 2 (8%) | 0.74b |
| Maternal diabetes | 3 (7%) | 2 (5%) | 0 | 0.79b |
| Maternal fever/infection prior to delivery | 5 (12%) | 6 (15%) | 4 (13%) | 0.8b |
| 1st minute Apgar score (Me; 25–75th percentile) | 2 (1–4) | 5 (4–6) | 5 (2–6) | 0.01c |
| 5th minute Apgar score (Me; 25–75th percentile) | 6 (4–6) | 7 (6-7) | 7 (6–8) | 0.001c |
| Delivery room intubation | 28 (69%) | 16 (40%) | 11 (33%) | 0.01b |
| Surfactant therapy | 33 (81%) | 29 (73%) | 14 (43%) | 0.003b |
| Initial a/A ratio | 0.31 ± 0.2 | 0.25 ± 0.13 | 0.44 ± 0.25 | 0.01a |
| Prenatal steroids | 10 (25%) | 12 (29%) | 22 (66%) | 0.01b |
| Ureaplasma infection | 12 (29%) | 8 (21%) | 6 (18%) | 0.28b |
| Pharmacological closure of patent ductus arteriosus | 22 (54%) | 23 (59%) | 11 (33%) | 0.08b |
| Surgical closure of patent ductus arteriosus | 18 (44%) | 4 (10%) | 2 (6%) | <0.001b |
| Length of mechanical ventilation (Me; 25–75th percentile) | 42 (25–52) | 3 (1–10) | 2 (0–6) | <0.001c |
| Bronchopulmonary dysplasia | 40 (98%) | 24 (62%) | 6 (18%) | <0.001b |
a P value for one-way analysis of variance.
b P value for chi-square test.
c P value for Kruskal-Wallis analysis of variance.
Summary of the number of differentially expressed genes between the studied groups.
| Comparison |
|
| |
|---|---|---|---|
| 5th DOL | Genes presented a positive monotone trend (expression in extremely preterm is lower than that in very preterm; expression in very preterm is lower than that in moderately preterm) | 56 | |
| Genes presented a negative monotone trend | 82 | ||
|
| |||
| 28th DOL | Genes presented a positive monotone trend | 253 | |
| Genes presented a negative monotone trend | 55 | ||
|
| |||
| 5th DOL versus 28th DOL (paired | Genes whose expressions were significantly higher on the 28th DOL compared to those on the 5th DOL | 1522 | 150 |
| Genes whose expressions were significantly lower on the 28th DOL compared to those on the 5th DOL | 2909 | 337 | |
|
| |||
| Extremely preterm infants measurement on the 28th DOL versus very preterm infants measurements on the 5th DOL | Genes whose expressions were significantly higher in the group of extremely preterm infants compared to those in the group of very preterm infants | 176 | 29 |
| Genes whose expressions were significantly lower in the group of extremely preterm infants compared to those in the group of very preterm infants | 186 | 27 | |
Summary of the pathway analysis for the differentially expressed genes between the groups. Pathways with FDR value less than 15% are shown.
| Input to pathway analysis | Pathway name | FDR (%) |
|---|---|---|
| Genes presented a positive monotone trend on the 5th DOL, adjusted for multiple comparison | T-cell receptor signaling pathway | 0.6 |
|
| ||
| Genes presented a negative monotone trend on the 5th DOL, adjusted for multiple comparison | No pathway | |
|
| ||
| Genes presented a positive monotone trend on the 28th DOL, adjusted for multiple comparison | Primary immunodeficiency | 0.01 |
|
| ||
| Genes presented a negative monotone trend on the 28th DOL, adjusted for multiple comparison | No pathway | |
|
| ||
| Genes whose expressions were significantly higher on the 28th DOL compared to those on the 5th DOL (paired | Graft-versus-host disease | <0.001 |
|
| ||
| Genes whose expressions were significantly lower on the 28th DOL compared to those on the 5th DOL (paired | Cell cycle | 0.27 |
|
| ||
| Genes whose expressions were significantly higher in the group of extremely preterm infants (measurements on the 28th DOL) compared to those in the group of very preterm infants (measurements on the 5th DOL); | Graft-versus-host disease | 0.01 |
|
| ||
| Genes whose expressions were significantly lower in the group of extremely preterm infants (measurements on the 28th DOL) compared to those in the group of very preterm infants (measurements on the 5th DOL); | No pathway | |